MarketPulse

FDA Fast Track designation

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Incannex Healthcare Inc.

Incannex Accelerates Sleep Apnea Drug After FDA Fast Track Win, Phase 2 Success

Incannex Healthcare receives FDA Fast Track Designation for IHL-42X sleep apnea treatment following positive Phase 2 results, plans optimized Phase 3 pathway.
IXHLPhase 2 clinical trialdrug development
GlobeNewswire Inc.GlobeNewswire Inc.··Na

OKYO Pharma's Neuropathic Eye Pain Therapy Earns ARVO 2026 Presentation Slot

OKYO Pharma's urcosimod earns ARVO 2026 presentation slot for neuropathic eye pain therapy. Phase 2a data shows pain reduction and quality-of-life improvements; Phase 2b/3 trial planned for 2026.
OKYOclinical trial resultsneuropathic corneal pain